oral glp-1 medication Novo Nordisk's drug didn't work on Alzheimer's as hoped, but don't call it a failure Eli Lilly's oral GLP-1 pill

However, skin permeability challenges and variable absorption rates mean efficacy data remain preliminary

Advances Continue Across the GLP-1 Landscape Momentum across the GLP-1 and metabolic disease sector continues to accelerate as leading biotechnology and pharmaceutical companies expand development programs targeting obesity, diabetes, liver disease and broader cardiometabolic conditions

People with type 2 diabetes, especially those taking a GLP-1 drug, should be aware of the signs and symptoms of vision loss and consult with their doctor immediately

While GLP-1 agonists don't require specific dietary patterns, emphasizing whole foods, adequate protein (generally 0.8-1.2 g/kg body weight, with higher amounts individualized based on health status), and fiber (25-35 g daily) enhances satiety